Antiretroviral therapy coverage in Morocco
Morocco: Antiretroviral therapy coverage was 76.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Morocco, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
Morocco recorded 76.0% for antiretroviral therapy coverage in 2024. That is the highest value across all 25 years on record.
That represents a change of up 4.1% on the previous year and up 130.3% over ten years.
Over the whole period, antiretroviral therapy coverage in Morocco peaked at 76.0% in 2024 and was at its lowest, 0.0%, in 2000.
That places Morocco 61st out of 143 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Morocco, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 4.0% | — |
| 2004 | 6.0% | +50.0% |
| 2005 | 7.0% | +16.7% |
| 2006 | 8.0% | +14.3% |
| 2007 | 9.0% | +12.5% |
| 2008 | 12.0% | +33.3% |
| 2009 | 14.0% | +16.7% |
| 2010 | 16.0% | +14.3% |
| 2011 | 19.0% | +18.8% |
| 2012 | 25.0% | +31.6% |
| 2013 | 29.0% | +16.0% |
| 2014 | 33.0% | +13.8% |
| 2015 | 37.0% | +12.1% |
| 2016 | 41.0% | +10.8% |
| 2017 | 44.0% | +7.3% |
| 2018 | 48.0% | +9.1% |
| 2019 | 51.0% | +6.2% |
| 2020 | 54.0% | +5.9% |
| 2021 | 68.0% | +25.9% |
| 2022 | 70.0% | +2.9% |
| 2023 | 73.0% | +4.3% |
| 2024 | 76.0% | +4.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 6.0% | 0.0% | 14.0% | 10 |
| 2010s | 34.3% | 16.0% | 51.0% | 10 |
| 2020s | 68.2% | 54.0% | 76.0% | 5 |
Countries ranked near Morocco
- 59 Nepal 77.0% compare
- 59 United Arab Emirates 77.0% compare
- 61 Canada 76.0% compare
- 61 El Salvador 76.0% compare
- 61 Mauritania 76.0% compare
More health data for Morocco
- Un projection of annual infant deaths, annual growth rate -1.91 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6655 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,240 deaths per 1,000 people (2090)
- Number of infants who die before age 1 925 deaths (2100)
- Population ages 05-09, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, female, per capita 0.0411 units per person (2025)
- Population ages 05-09, male, annual growth rate -0.6119 % change on previous year (2025)
- Population ages 05-09, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, male, per capita 0.0432 units per person (2025)
- Population ages 10-14, female, annual growth rate -0.7687 % change on previous year (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Morocco?
- Antiretroviral therapy coverage in Morocco was 76.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Morocco?
- The highest recorded value was 76.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Morocco?
- The lowest recorded value was 0.0% in 2000.
- How does Morocco rank for antiretroviral therapy coverage?
- Morocco ranks 61st out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Morocco?
- Over the last ten years it is up 130.3%. The long-run trend across the full record is volatile.
- Where does this Morocco data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.